ALLEN MEGLIN, MD
Medical Advisory Board
Regenerative Medicine Technology
Dr. Allen Meglin sits on the Medical Advisory Board in the areas of Regenerative Medicine Technology for American Health.
Doctor Meglin attended University of Pittsburgh School of Medicine where he was class president. After graduating at the top of his class and being inducted into the AOA medical honor society, he did a categorial surgical internship at Walter Reed Army Medical Center. His radiology residency and fellowship in Interventional Radiology were at Walter Reed and the Johns Hopkins Hospital. After training, he was the director of Interventional Radiology at Walter Reed, where he earned awards for teaching and research. He led workshops and presented research at national meetings, including the RSNA and SCVIR (now SIR).
He was a distinguished reviewer for the society journal (JVIR), edited a textbook on minimally invasive genitourinary interventions, published several peer reviewed articles, and taught at several Washington DC area medical schools. Dr Meglin then went into private practice where he did research on vascular stents, stent grafts, anticoagulants and thrombolytics. While there, he created a multidisciplinary endovascular service.
In the later part of his career, Dr Meglin developed an interest in Regenerative Medicine. Current research centers on minimally invasive treatments of joint disease, COVID-19, and men’s and women’s health. He sits on the board of directors of a regenerative medicine company and is a medical advisor to several medical device and supply companies. Dr Meglin holds four medical device patents which he has licensed to industry. He has a patent pending in regenerative medicine. He practices now in Savannah Georgia, overseeing three regenerative medicine clinics. He is the founder of Advanced Regenerative Therapy and the Georgia Institute for Regenerative Medicine. He is currently participating in FDA trials to treat COVID- 19 with Regenerative Medicine products. He just completed a study using platelet rich plasma as a tissue adhesive to minimize post biopsy complications.